屈大麻酚作为治疗艾滋病患者体重减轻相关厌食症的药物。

Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS.

作者信息

Beal J E, Olson R, Laubenstein L, Morales J O, Bellman P, Yangco B, Lefkowitz L, Plasse T F, Shepard K V

机构信息

St. John's Hospital, Tulsa, Oklahoma, USA.

出版信息

J Pain Symptom Manage. 1995 Feb;10(2):89-97. doi: 10.1016/0885-3924(94)00117-4.

DOI:10.1016/0885-3924(94)00117-4

PMID:7730690

Abstract

The effects of dronabinol on appetite and weight were evaluated in 139 patients with AIDS-related anorexia and > or = 2.3 kg weight loss in a multi-institutional study. Patients were randomized to receive 2.5 mg dronabinol twice daily or placebo. Patients rated appetite, mood, and nausea by using a 100-mm visual analogue scale 3 days weekly. Efficacy was evaluable in 88 patients. Dronabinol was associated with increased appetite above baseline (38% vs 8% for placebo, P = 0.015), improvement in mood (10% vs -2%, P = 0.06), and decreased nausea (20% vs 7%; P = 0.05). Weight was stable in dronabinol patients, while placebo recipients had a mean loss of 0.4 kg (P = 0.14). Of the dronabinol patients, 22% gained > or = 2 kg, compared with 10.5% of placebo recipients (P = 0.11). Side effects were mostly mild to moderate in severity (euphoria, dizziness, thinking abnormalities); there was no difference in discontinued therapy between dronabinol (8.3%) and placebo (4.5%) recipients. Dronabinol was found to be safe and effective for anorexia associated with weight loss in patients with AIDS.

摘要

在一项多机构研究中，对139例患有艾滋病相关厌食症且体重减轻≥2.3千克的患者评估了屈大麻酚对食欲和体重的影响。患者被随机分配接受每日两次2.5毫克屈大麻酚或安慰剂治疗。患者每周3天使用100毫米视觉模拟量表对食欲、情绪和恶心进行评分。88例患者可进行疗效评估。屈大麻酚与基线以上食欲增加相关（安慰剂组为8%，屈大麻酚组为38%，P = 0.015），情绪改善（安慰剂组为-2%，屈大麻酚组为10%，P = 0.06），恶心减轻（安慰剂组为7%，屈大麻酚组为20%；P = 0.05）。屈大麻酚治疗的患者体重稳定，而接受安慰剂的患者平均体重减轻0.4千克（P = 0.14）。在屈大麻酚治疗的患者中，22%体重增加≥2千克，而安慰剂组为10.5%（P = 0.11）。副作用大多为轻至中度（欣快感、头晕、思维异常）；屈大麻酚组（8.3%）和安慰剂组（4.5%）的停药率无差异。研究发现，屈大麻酚对艾滋病患者伴有体重减轻的厌食症安全有效。